Nutrien Ltd. (NYSE: NTR) — The World’s Low-Cost Rock, Priced for the Middle of the Cycle

Independent research note. Report date: 2026-07-03. Price referenced: $65.06 (2026-07-02 close).

This article discusses valuation only as embedded expectations and scenarios. The analysis sections contain no buy/sell recommendation and no price target. The single, deliberate exception is the Author’s Take block immediately below, which is fenced off as a subjective personal view.

⚡ Author’s Take

This block is the author’s own subjective opinion and general information only. It is not investment advice. The analysis that follows takes no position and carries no price target.

Verdict: HOLD / a cost-advantaged cyclical fairly priced at mid-cycle / accumulate-on-weakness toward the mid-to-high $50s / not-a-short. Medium conviction.

After a month of writing up businesses trading at their richest-ever multiples, Nutrien is a change of scenery: it is one of the few large-caps I have looked at recently that is not expensive on its own history. The composite own-history valuation sits at the 50.5th percentile — dead-center of its decade — with a 13.2x trailing P/E (34th percentile) and a 1.24x book (66th). That matters because Nutrien owns the single best physical asset in the fertilizer world: bottom-quartile Saskatchewan potash, a multi-decade reserve base mined at a controllable cash cost under ~$60/tonne while the marginal producer (K+S) breaks even near $350/tonne. That is a real Greenwald cost/resource moat, and it is the reason Nutrien stays cash-generative through troughs that shut its competitors. Bolt on the largest ag-retail distribution network in North America (Nutrien Ag Solutions, a genuine scale/density moat that held gross margin flat — $4.62B → $4.60B — straight through the 2023–24 fertilizer crash), and you have a business whose downside earnings power is deep and defensible.

But I will not oversell it, because the numbers won’t let me. This is a capital-heavy, price-taking commodity company that earns roughly its cost of capital through the cycle — through-cycle ROIC ~7–8% (20.7% at the 2022 peak, 4.9% at the 2024 trough, 7.8% in 2025), not a compounder. Three of its four segments have no pricing power; only potash is a franchise, and even that confers trough survival and relative margin, not price-setting. Capital allocation has been the tell: management bought back $4.35B of stock at the ~$90 2022 peak (underwater today at $65) and only $190M at the ~$47 2024 trough, and rolled up a Brazilian retail empire at the top that it is now impairing and pruning at a loss. The current Seitz regime — capex discipline, ~$200M of cost cuts pulled forward, ~$900M of divestitures, a growing dividend, deleveraging to ~1.6x — is materially better, but it is a correction of prior mistakes, not proof of a great steward. And the near-term print is flattered: a chunk of 2026 upstream EBITDA is a transient Iran/Strait-of-Hormuz nitrogen premium that is already unwinding, while a genuine new-supply overhang (BHP’s Jansen greenfield from 2027 + fully-recovered Belarus/Russia exports) caps the potash upcycle.

So this is a good-not-great business at a fair-to-slightly-cheap price — framed correctly as an out-of-favor, low-beta (0.41) value/commodity name at mid-cycle, not a momentum trade and not a falling knife (the multi-year trend is a wide sideways channel, not a collapse; a quantitative factor model shows it loading OilPrice ~0.65 and Value ~0.47, a classic cheap-cyclical signature). At $65 the market is underwriting a normalized ~$6.2B EBITDA at ~6.5x — reasonable, and it gives away little credit for either durable potash tightness or a prolonged Hormuz premium. The math: ~6.5x on ~$6.0–6.5B mid-cycle EBITDA less ~$10B net debt over 482M shares lands equity around $58–66/share; the potash-durability upside gets you to the high-$70s, a hard trough to the low-$40s. My accumulation zone is the mid-to-high $50s, where you are paid the cost-curve advantage and the ~3.4% dividend without underwriting the transient nitrogen spike. Conviction: medium. Flips bullish if potash tightness proves structural (China/India contract prices ratchet higher, Belarus exports stall, farmer application rates fully recover) while the balance sheet keeps de-levering and the new 5% buyback is spent counter-cyclically. Flips bearish if Jansen ramps into a Belarus/Russia-normalized market and potash reverts toward $250–300/tonne while Retail Brazil re-impairs. Tag: the world’s cheapest rock, priced about right — own the trough survivor, don’t pay for the spike.

📈 Stock Price Action — Five-Year Event Map

Factual price history — not a recommendation, not a price target.

The arc (FACT, public price history, adjusted close, 2018→2026-07-02). Over the last five years Nutrien ran a full commodity round-trip and is now mid-channel. The stock bottomed at a split/dividend-adjusted $19.86 (18-Mar-2020, COVID crash), reflated through the 2021 ag boom, and spiked to an all-time adjusted-close high of $98.48 (18-Apr-2022) on the Russia/Ukraine potash super-shock. It then collapsed with fertilizer prices to a cycle low near $41 (Dec-2024) as potash fell from ~$1,200/t toward the $300s and the EPS trough printed ($1.36). A 2025 recovery and a 2026 Iran/Strait-of-Hormuz nitrogen supply shock carried it to a 52-week high of $82.59 (12-Mar-2026); it has since retraced to $65.06 (2-Jul-2026) as the geopolitical premium unwinds. That leaves the stock roughly −34% off the 2022 all-time high and −21% off the March-2026 52-week high, with a 52-week range of $52.32 (4-Nov-2025) → $82.59. This is the signature of a low-beta (0.41) energy/commodity-correlated instrument (dominant quantitative factor: OilPrice β~0.65), not a compounding franchise.

Cycle narrative. (1–2) The 2020 crash and 2021 reflation are macro, not company-specific: Nutrien is a levered play on crop prices and planted acreage, and both boomed post-COVID. (3) The April-2022 all-time high was a pure supply shock — the sanctioning of Belarusian and Russian potash (together ~40% of seaborne supply) sent potash to ~$1,200/t and handed Nutrien a $12.2B EBITDA / $14.18 EPS windfall year. (4) That windfall reversed brutally: as Belarus/Russia exports found workarounds and farmers destocked and skipped applications, potash and nitrogen prices fell for two years, EBITDA halved to $5.4B, GAAP EPS bottomed at $1.36 (a $530M impairment year), and the stock round-tripped to ~$41. (5) The 2025 recovery was price- and volume-led (potash +$37/t on record volumes, nitrogen +$41/t), and in early 2026 an Iran/Hormuz conflict that disrupted >30% of global urea trade spiked nitrogen and phosphate, carrying NTR to $82.59. (6) Since June 2026, US–Iran de-escalation and a “Hormuz reopening” narrative have unwound that premium, and a widely-circulated note flagged Q2 consensus as too high — retracing the stock to $65. Each price move is a FACT (price history); each attributed cause is INTERPRETATION cross-referenced to earnings prints, benchmark-price data, and the news feed.

1. Executive Summary

Nutrien is the product of the 2018 merger of PotashCorp and Agrium — the world’s largest potash producer, a top-tier low-cost nitrogen producer, a subscale phosphate operation, and, uniquely among fertilizer majors, the largest agricultural retailer in North America (Nutrien Ag Solutions). FY2025 revenue was $26.9B, adjusted EBITDA $6.05B, diluted EPS $4.66, with the four operating segments contributing roughly: Potash $2.25B, Nitrogen $2.15B, Retail $1.74B, Phosphate $0.38B of adjusted EBITDA.

The investment case rests on one genuinely durable asset and one genuine stabilizer. The asset is Saskatchewan potash: bottom-quartile cost curve, multi-decade reserve life, controllable cash cost under ~$60/tonne, mined and exported through the Canpotex logistics scale advantage. The stabilizer is Retail, whose gross margin was essentially flat ($4.62B → $4.60B) straight through the 2023–24 fertilizer collapse — a scale/density distribution moat that dampens the group’s commodity beta. Together they give Nutrien deep, defensible trough earnings power (~$5B EBITDA / positive FCF even at the bottom).

The case against paying up is equally clear. This is a capital-consumptive, price-taking commodity business that earns roughly its cost of capital across the cycle (through-cycle ROIC ~7–8%). Three of four segments have no pricing power; potash confers survival and relative margin, not price-setting. Capital allocation has historically been pro-cyclical and value-destructive — $4.35B of buybacks at the 2022 peak, a debt-funded Brazil retail roll-up now being impaired and pruned — though the current regime is a genuine improvement. And near-term earnings are flattered by a transient Iran/Hormuz nitrogen premium that is unwinding, against a structural new-supply overhang (BHP Jansen from 2027 + recovered Belarus/Russia potash) that caps the best segment.

Crucially, unlike most large-caps we have reviewed this quarter, Nutrien is not expensively priced. It trades at ~6.8x EV/EBITDA and the 50.5th percentile of its own decade-long valuation range. At $65 the market is underwriting a normalized mid-cycle Nutrien (~$6.2B EBITDA at ~6.5x), extrapolating neither the 2024 trough nor the 2026 spike. That is a reasonable, slightly conservative embedded expectation. The variant question is whether potash tightness is structural (upside) or whether Jansen + Belarus/Russia normalization re-fragments the oligopoly and reverts potash toward $250–300/t (downside). The analysis below argues the truth is in between, and the price broadly reflects it.

2. Business Overview

Nutrien Ltd. is a Saskatoon-headquartered, USD-reporting Canadian company (IFRS filer; files 40-F/6-K with the SEC as a foreign private issuer). It operates four reportable segments across two fundamentally different businesses — upstream crop-nutrient production (Potash, Nitrogen, Phosphate) and downstream agricultural retail distribution (Retail / Nutrien Ag Solutions).

Potash (FY2025 adj EBITDA ~$2.25B, ~35% of segment EBITDA). Nutrien is the world’s #1 potash producer, with six mines in Saskatchewan (of Canada’s ten) and ~20Mt of operational capability. FY2025 sales volume was 14,253kt at an average net realized price of ~$252/t (up from 13,886kt @ $215/t in 2024) — a price- and volume-led rebound. Controllable cash cost of product manufactured held under $60/t into Q1 2026, implying segment EBITDA of ~$158/tonne. Offshore volumes are marketed through Canpotex, the Saskatchewan export JV Nutrien co-owns with Mosaic. This is the crown jewel.

Nitrogen (FY2025 adj EBITDA ~$2.15B, ~33%). Ammonia, urea, ESN (controlled-release), nitrogen solutions, nitrates and sulfates, produced primarily on cheap Western-Canadian/US-Gulf natural gas. FY2025 volume was 10,888kt at ~$365/t (2024: 10,694kt @ $324/t). Gas is 70–90% of cash cost; Nutrien sits in the first quartile of the global cost curve alongside CF Industries and Koch. Nitrogen is a low-cost-shared business, not a franchise.

Retail — Nutrien Ag Solutions (FY2025 adj EBITDA ~$1.74B, ~27%). The largest ag retailer in North America — >1,500 outlets across 45 US states and Canada, plus Australia and Brazil — ranked #1 on the CropLife 100. It distributes crop protection, crop nutrients, seed, merchandise, and agronomic services, and extends grower credit through Nutrien Financial. FY2025 gross margin by line: Crop Protection $1,590M, Crop Nutrients $1,424M, Services & Other $750M, Seed $408M, Nutrien Financial $376M, Merchandise $148M. Proprietary (private-label, higher-margin) products contributed $1,104M of gross margin (up from $1,060M) — the mix lever management is pushing. Retail is a distribution/services business: ~38% EBITDA-to-gross-margin conversion, ~12% EBITDA margin on ~$14B of sales, carrying heavy Agrium/UAP-legacy goodwill.

Phosphate (FY2025 adj EBITDA ~$0.38B, ~6%). Solid and liquid fertilizer plus industrial/feed products. The smallest and structurally weakest segment — a price-taker squeezed by sulfur/ammonia input costs and international supply (OCP/Morocco, Mosaic), and the recurring source of impairments. Under strategic review for potential sale.

The Canpotex logistics advantage. A structural feature worth isolating: Nutrien’s offshore potash is marketed and shipped through Canpotex, the export joint venture it co-owns with Mosaic, which aggregates Saskatchewan production and controls dedicated rail and port terminal capacity (Vancouver, Prince Rupert, Portland, Saint John) for delivery to Asia, Latin America and other seaborne markets. This is a genuine scale/infrastructure barrier — a new entrant cannot replicate decades of rail contracts and terminal ownership overnight, and it is a large part of why the Saskatchewan producers sit at the bottom of the delivered cost curve, not just the mine-gate cost curve. Canpotex also enforces a degree of volume discipline in the seaborne market. Domestic (North American) potash is sold directly. The distinction matters because BHP’s Jansen mine will have to build or buy its own logistics chain to compete on delivered cost — a friction that partly offsets its greenfield mine-gate economics.

How the upstream actually earns. Potash economics are volume-and-price against a mine cash cost that is nearly fixed: at a ~$252/t FY2025 realized price against <$60/t controllable cash cost, the incremental margin on each additional tonne is enormous, which is why volume flex (Nutrien can ramp Saskatchewan output cheaply) is such a powerful earnings lever in a firming market — and why the segment’s EBITDA/tonne (~$158 in 2025) swings so violently with price. Nitrogen is a spread business: the global clearing price is set by the marginal European producer paying TTF gas at ~$15–16/MMBtu, while Nutrien pays Henry Hub/AECO nearer ~$3, so its rent is essentially the gas-cost differential times volume — a rent that widens in energy crises (2022, the 2026 Hormuz shock) and compresses when global gas normalizes. Phosphate earns a thin, input-cost-squeezed margin on rock, sulfur and ammonia. Retail earns a stable distribution/services margin largely decoupled from fertilizer prices (it passes crop-nutrient costs through) but tied to fertilizer and crop-input volumes and to grower financial health.

How it makes money and revenue mix. Roughly 70–75% of segment EBITDA in an up-year (2025) is upstream commodity fertilizer — price × volume against benchmark potash, urea, ammonia and DAP/MAP prices — and ~27% is Retail distribution margin. Revenue is highly cyclical and largely non-recurring in the upstream (spot/contract commodity sales), and more stable but low-margin in Retail (seasonal, tied to planted acreage, farmer income, and application rates). There is a meaningful seasonal working-capital swing (spring planting), so quarterly cash flow is noisy and should be read on a trailing-twelve-month basis. Retail’s own unit economics are worth restating plainly: ~$1.74B of adjusted EBITDA on ~$4.60B of gross margin and ~$14B of sales is a ~38% EBITDA-to-gross-margin conversion and a ~12% EBITDA margin — respectable for physical distribution, but a fraction of the potash segment’s ~60%+ EBITDA margin, and diluted at the return level by the ~$12B of goodwill the roll-up left on the balance sheet.

Verdict: A diversified crop-inputs business with a best-in-class upstream asset (potash), a competitive nitrogen operation, a marginal phosphate tail, and a scale-leading but low-return retail distributor. The economic center of gravity is potash; the stabilizer is Retail; the perennial capital sink has been Brazil/South-America retail and phosphate.

3. Industry Dynamics

Nutrien straddles two industries with very different structures.

Potash — a concentrated, disciplined oligopoly (the good one). The top five producers (Nutrien, Uralkali, Belaruskali, Mosaic, K+S) supply roughly 80% of the global market; the broader top seven, ~70–75%. Historically two seaborne marketing channels dominated — Canpotex (Nutrien + Mosaic, Saskatchewan export JV) and BPC (Belaruskali/Uralkali). Barriers to entry are high: a greenfield mine costs billions and takes a decade, and the incentive price for new supply (>$500/t) sits well above the current ~$350/t MOP price — a ~$150/t gap that has historically choked new sanctioning. The Saskatchewan cost curve is bottom-quartile; K+S (mid-curve) roughly breaks even at ~$350/t. This is the most attractive sub-industry Nutrien touches.

But two supply developments are eroding the discipline. First, BHP’s Jansen greenfield in Saskatchewan begins production around mid-2027 at ~8.5Mtpa (Stage 1), with a potential path to 16–17Mtpa — the first major new low-cost entrant into the oligopoly in decades. Second, Belarusian and Russian supply has largely recovered from the 2022 sanctions shock: Belarus exported ~11.6Mt in 2025 (near its pre-2022 ~12Mt) via Russian ports, the US lifted Belarus potash sanctions in 2025, and Russia ships ~12–13Mt. The very supply disruption that drove the 2022 super-spike has substantially unwound. In Marathon capital-cycle terms, potash sits in early recovery with a visible new-supply overhang — the classic condition that caps an upcycle.

Nitrogen — gas-cost-driven and regionally fragmented (mediocre). The global nitrogen price is set by the marginal high-cost producer — typically European (e.g., Yara) operating on TTF gas at ~$15–16/MMBtu versus Henry Hub ~$3. North-American producers on cheap gas earn the spread. But the industry has “limited barriers to entry,” competes on delivered price, and offers no pricing power to any single producer. It is a spread business, not a franchise.

Phosphate — internationally over-supplied (weak). OCP (Morocco) and Mosaic dominate; the product is a price-taker squeezed between rock/sulfur/ammonia input costs and international supply. Structurally the weakest fertilizer, and the reason Nutrien’s phosphate assets have impaired repeatedly.

Potash demand — the agronomic case and its limits. The bull framing for potash rests on a real agronomic fact: potassium is a non-substitutable macronutrient with no synthetic alternative, and under-application depletes soil reserves that must eventually be replenished. When prices spiked in 2022 farmers “mined the soil” — skipping applications and drawing down soil potassium — which set up a demand rebound as they must eventually re-apply to sustain yields. Brazil and China potash inventories reached multi-year lows in 2025–26, supporting the restocking thesis. But the limit is equally real: potash demand is price-elastic in the short run (farmers can defer a season or two), volume grows only ~2–3%/year secularly with global food demand, and the demand recovery is a normalization, not a growth engine. The agronomic floor supports the trough; it does not underwrite a permanent high price.

Ag retail — fragmented but consolidating (structurally OK, low-growth). US ag retail is consolidating: the top-8 retailers are now ~70% of CropLife 100 sales, and Nutrien is #1. But demand is tied to farmer income, crop prices, planted acreage and application rates — cyclical, not secular — and margins are thin. It is a better business than commodity fertilizer (more stable, scale-advantaged) but not a growth industry. A structural watch-item is disintermediation risk: digital-ag platforms and direct-to-grower input models could, over a long horizon, erode the agronomy-advice and product-distribution margin that underpins Retail — which is precisely why management is investing in its own digital platform and in higher-margin proprietary products to defend the relationship.

Verdict: a structurally mediocre set of industries with one genuinely good sub-segment. Commodity fertilizer is capital-intensive, cyclical and price-taking — through-cycle excess returns are thin and mean-reverting. Potash is the best of the lot (disciplined oligopoly, high barriers, bottom-of-curve economics) but faces a rising supply overhang. Ag retail is a better, stickier distribution business but low-margin and low-growth. This is not an industry that structurally compounds capital; it is one where the low-cost survivor wins relative — and Nutrien is that survivor in potash.

4. Competitive Position

The moat analysis must be done segment by segment, because Nutrien’s “moat” is real where it can be tied to a financial outcome and absent where it cannot.

Potash — a genuine Greenwald supply/cost + privileged-resource advantage. Nutrien’s Saskatchewan reserves are bottom-quartile-cost, multi-decade-life, and mined at a controllable cash cost under ~$60/t. The financial tell is decisive: Nutrien earns ~$158/t of segment EBITDA at a $252 realized price while K+S (mid-curve) breaks even near $350/t. In other words, Nutrien profits through troughs that render its marginal competitors cash-negative and force curtailments. That is a durable cost moat tied directly to a financial outcome (trough survival + relative margin). But there is no individual pricing power — Nutrien is a price-taker on a globally-traded commodity, and it curtails volume to defend price alongside the oligopoly. The moat is survival and relative margin, not price-setting; in Greenwald’s taxonomy, “privileged access to a low-cost resource.”

Retail — a real but modest economies-of-scale / distribution-density moat with moderate customer captivity. Nutrien Ag Solutions’ advantage is local scale, outlet density, agronomy relationships, embedded grower credit (Nutrien Financial), a digital platform, and proprietary private-label products. The financial tell is gross-margin stability: $4.62B (2024) → $4.60B (2025) straight through the fertilizer crash, versus a Potash EBITDA swing of hundreds of millions. That validates Retail as ballast. But the moat is the weakest Greenwald form — local scale plus search/switching costs — and it shows up as stability, not high returns: ~12% EBITDA margin, pedestrian ROIC diluted by heavy goodwill. Some pricing/mix power exists via proprietary products (~$1.1B gross margin, growing) and services ($750M), which is the lever that could modestly lift returns over time.

Nitrogen — a shared cost advantage, not a franchise. Nutrien is a low-cost producer, not the low-cost producer; it shares cheap North-American gas with CF, Koch and CVR, and competes globally with cheaper Russian/Gulf feedstock. It generates transient rent when gas spreads are wide, but has no pricing power and no durable edge over its domestic peers.

Phosphate — no moat. Subscale versus OCP/Mosaic, cost-position-dependent, impairment-prone.

Direct competitor comparison. Against Mosaic, Nutrien’s closest potash-plus-phosphate peer and Canpotex co-owner, Nutrien is larger, lower-cost in potash, and carries the offsetting Retail annuity Mosaic lacks — but Mosaic is a more concentrated (higher-beta) potash/phosphate play. Against K+S (mid-curve, ~$350/t breakeven), Nutrien’s cost advantage is decisive — K+S is the marginal producer Nutrien profitably outlasts. Against CF Industries in nitrogen, the two share the North-American gas advantage, but CF is the purer, lower-cost, fortress-balance-sheet nitrogen operator (~0.4x net debt/EBITDA vs Nutrien’s ~1.66x) — Nutrien’s nitrogen is competitive but not category-leading, and CF is the better vehicle for a pure nitrogen view. Against ICL/OCP in phosphate, Nutrien is subscale and disadvantaged. The takeaway: Nutrien wins on breadth and potash cost leadership, not on being the best operator in any single upstream product except potash.

Greenwald tests. Share stability: Nutrien has held #1 global potash share and #1 US ag-retail share for years — stable shares signal barriers are present. Profitability: through-cycle consolidated ROIC is only ~7–8% (20.7% peak → 4.9% trough → 7.8% in 2025), which fails the 15–25% franchise bar. The reconciliation: barriers protect the players (survival, share) but the commodity segments do not earn durably above cost of capital, and Retail’s returns are diluted by goodwill.

Verdict: a collection of cost-advantaged, share-stable commodity franchises plus a scale-leading distributor — not a high-return compounder. The one genuinely durable moat is Saskatchewan potash, and even that confers survival and relative margin rather than pricing power. Retail is a legitimate but low-return scale moat. Where a moat can be tied to a financial outcome (potash trough margin; Retail gross-margin stability) it is real; where it cannot (nitrogen pricing, phosphate) it is absent. An honest read: Nutrien is a quality cyclical, not a franchise.

5. Growth History and Forward Opportunities

History is a cycle, not a growth trajectory. Revenue ran $20.9B (2020) → $27.7B (2021) → $37.9B (2022 peak) → $29.1B (2023) → $26.0B (2024 trough) → $26.9B (2025). EPS traced $0.81 → $5.52 → $14.18 → $2.53 → $1.36 → $4.66. There is no secular top-line growth here — only the amplitude of the fertilizer price cycle around a slowly-growing volume base. Potash and nitrogen volumes have grown modestly (potash 13.9Mt → 14.3Mt; nitrogen ~10.7Mt → 10.9Mt in 2024→2025), and Retail has grown mostly by acquisition. Organic volume growth is low-single-digit; the swing factor is price.

The abandoned growth ambition. In June 2022 (at the peak) management announced a plan to ramp potash capability to 18Mt by 2025. In 2023, after prices and volumes collapsed, that ramp was indefinitely paused/cancelled — an ill-timed, cycle-top expansion call that management has since disowned in favor of capital discipline. This is a useful marker of the prior regime’s judgment.

Forward opportunities (incremental, not transformational):

• Potash volume growth into a firming market — Nutrien can flex Saskatchewan volume up cheaply (brownfield, automation) as global shipments grow toward 74–77Mt, taking share as the low-cost swing producer. 2026 guidance is 14.1–14.8Mt.
• Retail proprietary-product and services mix — lifting private-label penetration (~$1.1B gross margin and growing) and high-margin agronomy/financial services is the clearest path to higher-return growth. Management guides high-single-digit proprietary-margin growth.
• Nitrogen brownfield/efficiency — low-cost debottlenecking on cheap gas; not a needle-mover.
• Portfolio simplification as “growth in quality” — exiting phosphate, Trinidad nitrogen, and rationalizing Brazil retail should raise consolidated returns even without top-line growth.

Verdict: low-quality growth in aggregate, with a modest high-quality kernel. The bulk of the “growth” is cyclical price recovery and low-return volume/M&A; the genuinely value-creating opportunity is narrow (potash share-of-a-growing-market at bottom-of-curve cost, and Retail proprietary mix). Investors should not underwrite Nutrien as a grower — they should underwrite it as a low-cost cyclical that recovers with the potash/nitrogen cycle and returns cash.

6. Financial Quality

Income statement (IFRS, FY2025). Sales $26,885M (+4% YoY); gross margin $8,347M; net earnings $2,297M (vs $700M in 2024); diluted EPS $4.66 (vs $1.36); adjusted EBITDA $6,046M (+13%); adjusted net earnings $2,216M / adjusted EPS $4.56. Segment adjusted EBITDA: Retail $1,741M, Potash $2,250M, Nitrogen $2,150M, Phosphate $382M, less Corporate/eliminations ~$(0.48)B.

A high-quality 2025, but “adjusted” flatters the through-cycle. The 2025 adjustments were small and net negative: the EBITDA→adjusted-EBITDA bridge stripped out a one-time $301M Profertil divestiture gain (adding back only $163M SBC, $9M FX, $68M restructuring), so adjusted EBITDA ($6,046M) sits below reported EBITDA ($6,105M) and adjusted net earnings ($2,216M) sits below reported net earnings ($2,297M). That is a green flag for 2025 specifically. The red flag is cross-cycle: “adjusted” earnings add back recurring impairments — $824M (2020), $774M (2023, incl. ~$465M South-America retail goodwill), $530M (2024, incl. $335M Brazil retail) — and the 2022 peak was flattered by a $780M impairment reversal. Because these write-downs recur every downcycle (phosphate + Brazil/S.America retail), cumulative “adjusted” EBITDA overstates true through-cycle economics. The impairments are the delayed cost of pro-cyclical M&A and should be amortized back into normalized earnings power.

Cash flow and the FCF reality. FY2025 operating cash flow was $4,007M; total capex $2,005M; simple owner FCF (OCF − capex) ~$2.0B. Note: ROIC’s headline “free cash flow” field of ~$4.0–4.6B equals operating cash flow (it does not net capex most years) and must not be used. D&A ($2,369M) ran above capex ($2,005M) in 2025 — Nutrien is in harvest/underinvest mode, which supports near-term FCF but is not indefinitely sustainable. Of the $2.0B capex, ~$400M is discretionary “investing” (proprietary products, Retail digital, nitrogen brownfield, potash automation), implying sustaining + mine-development capex of ~$1.6B; on a pure-sustaining basis owner FCF is closer to ~$2.4–2.5B. Working capital swings are large and seasonal (2025 was a $(783)M drag; 2023 was a +$507M release), so cash flow is noisy quarter to quarter.

Through-cycle earnings power. Adjusted EBITDA: peak $12,195M (2022) → recovery $7,073M (2021) → trough $5,355M (2024) → $6,046M (2025); the prior trough was $3,713M (2020). A reasonable mid-cycle normalized adjusted EBITDA is ~$6.0–6.5B (a stable ~$1.8–2.0B Retail base + ~$4.5B upstream at mid prices), a trough of ~$5.0–5.5B, and a peak of $10–12B. The trough is deep and well-supported because potash and nitrogen stay cash-generative and Retail counter-stabilizes. Economics do scale on the upstream (potash is a high-incremental-margin franchise) but do not compound in Retail/Brazil, where scale has repeatedly produced impairments rather than returns.

Balance sheet. Net debt ~$10.0B ex-leases (cash $701M; total borrowings ~$12.0B), ~$11.3B including ~$1.28B of capital leases. Net debt/adjusted EBITDA ~1.66x (2025) versus 1.98x (2024) — deleveraging, and inside the company’s ~2x mid-cycle target. Equity $25.4B, of which goodwill ($12.1B) + intangibles ($1.7B) is ~55% — the Agrium/retail roll-up legacy. Current ratio 1.34; small pension liability (~$221M). Ratings Moody’s Baa2 (stable, affirmed May-2025) and S&P BBB (stable) — solidly mid-investment-grade, no changes through Q1 2026.

A note on returns versus cost of capital. The single most important financial fact about Nutrien is that its through-cycle ROIC (~7–8%) sits at or barely above a reasonable weighted-average cost of capital for a Baa2/BBB, 0.41-beta commodity producer (call it ~8–9%). That is the quantitative expression of “quality cyclical, not franchise”: across a full cycle, Nutrien creates modest-to-neutral economic value on incremental capital, with the value creation concentrated in the potash peaks (20.7% ROIC in 2022) and the value destruction concentrated in the retail/phosphate impairments. A franchise earns 15–25% ROIC durably; Nutrien does not. This is not a reason to avoid the stock — it is a reason to (a) underwrite it as a cyclical bought at a sensible price rather than a compounder held forever, and (b) weight the dividend and buyback yield heavily in the total-return math, because multiple expansion and ROIC-driven compounding are unlikely to do the heavy lifting.

Verdict: economics improve with scale only in the upstream. Nutrien is a good-quality upstream franchise (low-cost potash, competitive nitrogen) plus a stable low-return Retail annuity, wrapped around a capital-consumptive Brazil/S.America retail and marginal phosphate tail that recurringly impairs. 2025 reported numbers are clean, but “adjusted EBITDA” overstates through-cycle economics by excluding recurring write-downs. Trough earnings power is deep and defensible; returns scale on potash, not on retail M&A.

7. Capital Allocation

This is the section where Nutrien’s history is least flattering, and where the recent trajectory is most encouraging.

Buybacks — textbook pro-cyclical (the central critique). Repurchases for cancellation ran ~$4,352M in 2022 (average price ~$90, at/near the commodity peak), $835M (2021), $1,014M (2023), only ~$190M in 2024 (3.94M shares at ~$47, the cycle low), and ~$560M in 2025 (9.83M shares at ~$56). Nutrien bought the most stock at the highest price and the least at the lowest — the inverse of value-creating capital allocation, and a large slug of the ~15% share-count reduction since 2021 (571M avg diluted → 482M shares) was retired underwater versus today’s $65. On 18-Feb-2026 the Board approved a new NCIB for up to 5% of shares (~24M) — a step-up whose timing this cycle is the thing to watch.

Dividend — the bright spot. The quarterly dividend was $0.545 in Q4 2025 (~$2.18/yr), raised every year since the 2018 formation. The 2025 payout ratio was ~46% of adjusted EPS; even at the 2024 GAAP trough ($1.36 EPS), the ~$1.06B of dividends was easily covered by $3.5B of operating cash flow. This is a safe, growing dividend across the full cycle because trough FCF stays positive — the single most reliable element of the capital-return story, and the ~3.4% yield is a real part of the total-return case.

Growth capex and M&A — bought high, now correcting. The June-2022 announcement to ramp potash to 18Mt (paused in 2023) was an ill-timed cycle-top call. The 2018–2022 debt-funded Retail roll-up — especially Brazil/South America, bought near the peak — produced the subsequent write-downs ($465M S.America goodwill 2023, $335M Brazil retail 2024). Nutrien is now retreating: it sold its 50% Profertil (Argentina) stake for a $301M gain (Q4 2025), is running a “margin improvement plan” for Brazil retail (idling blenders and locations, cutting headcount), is exploring a sale of the Brazilian soybean-seed business, has put phosphate and the Trinidad nitrogen operations under strategic review/sale, and has taken New Madrid nitrogen offline. This is classic buy-high-sell-low correction — value was destroyed on the way in and is being partially recovered on the way out.

The current regime is materially better. Under CEO Ken Seitz (permanent since 2022), Nutrien has cut capex ~$600M below the prior plan, delivered ~$200M of annual operating cost savings ahead of its 2026 target, executed ~$900M of divestitures, deleveraged from ~2.0x to ~1.66x, and grown the dividend — a Marathon-consistent pullback from strength-turned-weakness. But it is a correction of prior mistakes, not proof of a durably good allocator.

A governance caveat. As a foreign private issuer, Nutrien files no SEC DEF 14A; its management information circular (with exact compensation metrics) sits on Canada’s SEDAR, not in the EDGAR corpus. Public strategy language now centers on “structural free cash flow” and cash returns, suggesting FCF/cash-return-linked incentives, but this could not be verified from the SEC filings available here (open question).

Verdict: MIXED, improving. Legacy allocation (2019–2023) was pro-cyclical and value-destructive on both buybacks and M&A. The current discipline is real and welcome, but unproven across a full cycle. The decisive test will be whether the new 5% NCIB is spent counter-cyclically (buying weakness) this time — reversing the 2022 mistake — or whether the pattern repeats.

8. Changes and Headwinds — Last Two Years

Leadership and strategy. Ken Seitz became permanent CEO in 2022 and reset the strategy from volume growth to capital discipline, cost savings and free cash flow — cancelling the 18Mt potash ramp. A CFO transition ran through 2024. The narrative has shifted decisively toward “structural free cash flow” and cash returns.

Portfolio simplification (2025–26). An active pruning program: (a) phosphate strategic review / sale process (reported significant buyer interest); (b) Trinidad nitrogen shut down and up for sale (gas-supply and port-fee economics); © Brazil retail rationalization (idled 5 blenders, sold 3, idled 64 locations, headcount cuts) plus a Brazilian soybean-seed business for sale in H2 2026; (d) New Madrid nitrogen offline; (e) sale of the 50% Profertil stake (Argentina) for a $301M gain. The through-line is exiting low-return/marginal assets to lift consolidated returns.

The Iran/Strait-of-Hormuz supply shock (the dominant near-term swing). A Middle-East conflict closed the Strait of Hormuz around late-February 2026, disrupting >30% of global urea trade and ~25% of ammonia and phosphate. Urea spiked above $850/t (April 2026, +80% since February, the highest since 2022); Qatar suspended urea/ammonia/sulfur exports and Iran halted ammonia; the World Bank projected the fertilizer price index up ~30%+ in 2026 (urea ~+60%, MOP ~+12%). This inflated 2026 nitrogen and phosphate benchmarks above mid-cycle. As of June 2026, US–Iran de-escalation and a “Hormuz reopening” narrative are unwinding that premium — and a widely-circulated note flagged Q2 2026 consensus as “too high.” Interpretation: a chunk of 2026 upstream EBITDA is a transient geopolitical premium; potash firming, by contrast, is demand-driven and more durable.

Tariffs and trade politics. A February-2026 US executive order imposed a 25% across-the-board Canada tariff (10% on energy), but USMCA-compliant fertilizers — including Canadian potash — are effectively exempt. Since the US imports ~85–87% of its potash from Canada and Nutrien owns six of Canada’s ten mines, this was a bullet dodged, but it is a recurring political-risk overhang. Separately, a US administration probe into alleged price-fixing in Canadian fertilizer is a low-probability but non-zero tail risk.

Potash supply overhang. BHP’s Jansen greenfield (first production ~mid-2027, ~8.5Mtpa Stage 1) and fully-recovered Belarus/Russia exports (~22–25Mt combined, with US Belarus sanctions lifted in 2025) are the structural headwinds capping the potash upcycle.

Verdict: net thesis-neutral, tilting cautiously constructive on quality, cautious on price durability. The portfolio simplification and capital discipline genuinely strengthen the business; the tariff exemption removed a large risk; but the near-term earnings tailwind (Hormuz) is transient and the medium-term potash supply overhang is real. The durable improvements are structural; the near-term boost is not.

9. Risk Analysis (Risk Matrix)

The dominant risks are structural (potash supply overhang) and cyclical (commodity price reversion, no pricing power). There is no catastrophic-loss risk: the balance sheet is investment-grade, leverage is modest, the assets are long-life and hard, and the business generates positive free cash flow even at the trough. The realistic downside is multiple years of mediocre, cost-of-capital returns, not impairment of the enterprise.

10. Valuation Discussion (Embedded Expectations)

No price target and no recommendation — this section frames what the market is underwriting and the scenario mechanics.

Where it trades. At $65.06 the market cap is ~$31.3B and EV ~$42.6B (net debt ~$10.0B ex-leases). On FY2025 numbers that is ~6.8x EV/EBITDA, ~1.6x EV/Sales, ~13.2x P/E, ~1.24x P/B. Critically, own-history valuation percentiles put NTR at the 50.5th composite percentile — P/E 34th, P/B 66th, P/S 51st — i.e., mid-range on its own decade, not stretched. For a commodity name, P/B and P/S (which are less distorted by peak/trough earnings than P/E) are the more reliable own-history tells; both say Nutrien is priced in the middle of its range, not at an extreme.

Own-history multiple context. EV/EBITDA by year: 2018 9.4x, 2019 9.6x, 2020 10.1x, 2021 7.5x, 2022 4.1x (peak EPS collapses the multiple), 2023 6.6x, 2024 6.4x, 2025 6.6x. The current ~6.6–6.8x sits below the pre-supercycle 9–10x norm and within the de-rated 2022–25 commodity range — consistent with a market that no longer pays a growth multiple for fertilizer.

Embedded expectations. The central valuation task is normalizing mid-cycle EBITDA, because reported EBITDA swings from $5.4B (trough) to $12.2B (peak). Scenario mechanics (mid-cycle EBITDA × multiple → EV − ~$10B net debt → ÷482M shares):

At $65 the market is underwriting the base/mid-cycle case (~$6.2B EBITDA at ~6.5x). It is not extrapolating the 2024 trough (that maps to the low-$40s, where the stock sat in Dec-2024) nor the 2026 spike (~$80s, the March-2026 high). The embedded read: consensus prices a normalized-mid-cycle Nutrien, giving little credit to either durable potash tightness or a prolonged Hormuz premium — and equally not pricing a hard trough. That is a reasonable, slightly conservative expectation.

What the market is getting right and where it may be offsides. Right: refusing to pay a growth multiple for a low-growth, cost-of-capital-returning commodity business; refusing to capitalize the transient Hormuz premium. Potentially offsides: (bull) under-crediting the durability of potash tightness if farmer application rates fully recover and Belarus export logistics stay constrained; (bear) under-weighting the Jansen + Belarus/Russia supply overhang that could revert potash toward $250–300/t just as Nutrien’s best segment recovers. The 2026 guidance (Retail adj EBITDA $1.75–1.95B; potash 14.1–14.8Mt at <$60/t cash cost; nitrogen 9.2–9.7Mt; capex $2.0–2.1B) is consistent with the base case.

A dividend-anchored total-return frame. Because ROIC compounding is unlikely to drive returns, the sensible way to think about the return math is yield-plus-normalization. At $65 the stock pays a ~3.4% dividend that is safe and has grown every year since 2018; the new 5% NCIB, if fully executed, adds another ~5% of potential share-count reduction (though management rarely runs it at full pace). Add ~1–2% of long-run volume/mix growth and the pre-cyclical-swing base return is roughly a high-single-digit yield-and-growth package — before any move in potash/nitrogen prices, which is the wildcard that turns a mediocre year into a great one or a poor one. That framing clarifies why the name suits a value/income mandate rather than a growth mandate, and why entry multiple matters so much: paying 6.5x mid-cycle preserves the yield-and-normalization return, whereas paying the 2022-peak multiple (or price) destroyed it.

Comps. NTR at ~6.6–6.8x EV/EBITDA sits mid-pack among fertilizer commodity peers — above CF Industries’ ~5.8x (nitrogen pure-play, fortress balance sheet, “priced for the crisis to last”), within the Mosaic range, and far below higher-quality ag-input franchises like Corteva (~14x, seed/crop-protection, richest-ever multiple). Nutrien’s small premium to pure-upstream peers is justified by Retail’s stabilizer earnings and potash cost-curve leadership. It is not cheap versus CF on a pure-multiple basis, but it is more diversified and less balance-sheet-levered to a single commodity.

Verdict: The valuation is fair-to-slightly-cheap on mid-cycle economics and squarely mid-range on its own history — a rare thing among large-caps in the sector. The stock is a reasonable expression of “own the low-cost potash survivor at a normal multiple,” with the variant being potash-durability, not multiple re-rating.

11. Variant Perception

Consensus belief. Sell-side is neutral-to-modestly-constructive: a value/commodity name off its relative-strength peak (−33.9%), low-beta (0.41), oil-correlated (OilPrice β ~0.65), recovering from the 2024 trough. Scotiabank upgraded to Sector Outperform (PT $80) on 30-Jun-2026; the stock screens “oversold” on materials RSI. But a circulating note flags Q2 2026 consensus as “too high,” reflecting the unwinding Hormuz premium. Consensus, in short, sees a fairly-valued mid-cycle recovery story with a transient nitrogen boost fading.

The strongest bull case. Potash tightness is structural, not transient. Global potash demand recovers as farmer application rates normalize (Brazil/China inventories are at multi-year lows), the incentive-price gap (>$500/t vs ~$350/t) keeps new supply choked beyond Jansen, Belarus export logistics stay constrained, and Nutrien — the low-cost swing producer — grows volume into a firming price. Retail lifts proprietary-product mix and returns. Free cash flow compounds, the balance sheet de-levers below 1.5x, and the new 5% NCIB is spent counter-cyclically. In this world mid-cycle EBITDA is ~$7B+, and the stock re-rates toward the high-$70s/low-$80s.

The strongest bear case. BHP Jansen ramps (2027→) into a fully-recovered Belarus/Russia market, re-fragmenting the seaborne oligopoly and reverting potash toward $250–300/t. The Hormuz premium collapses, taking nitrogen back to mid-cycle or below. A crop-price/farm-income downturn hits fertilizer prices and Retail volumes simultaneously; Brazil retail re-impairs; and management repeats its pro-cyclical buyback. Mid-cycle EBITDA proves closer to ~$5.0–5.5B, ROIC sits stuck below cost of capital, and the stock drifts to the low-$40s — where it traded as recently as December 2024.

The 3–5 assumptions that matter most:

1. Normalized potash price ($250 vs $300 vs $350/t) — the single biggest EBITDA swing factor.
2. Jansen + Belarus/Russia supply trajectory — determines whether the oligopoly holds its discipline.
3. Durability of the 2026 nitrogen premium — transient (base) vs persisting into 2027 (bull).
4. Retail return trajectory — whether proprietary mix and Brazil pruning lift ROIC, or Brazil re-impairs.
5. Capital-allocation discipline — counter- vs pro-cyclical NCIB timing this cycle.

What would falsify each side. Bull falsified if potash contract prices (China/India) roll over as Jansen ramps and Belarus exports climb — proving the tightness was cyclical. Bear falsified if potash holds $350+/t through Jansen’s ramp with disciplined oligopoly curtailment and Nutrien grows volume profitably — proving structural tightness.

Factor/positioning read (a quantitative factor model). Nutrien is not a crowded momentum trade; it is an out-of-favor, low-beta value/dividend commodity name — OilPrice β ~0.65, Value β ~0.47, Materials/Canada tilts, beta 0.41, y1 return +12.2% but a weak last quarter (m3 −42.8% annualized, the March→June retrace). Where consensus may be offsides: it is pricing the transient nitrogen premium correctly (fading it) but may be under-crediting the durability of potash tightness — the variant that separates the base from the bull. This is a name where the tape and the cheap-value factor loading both say “abandoned, mid-cycle,” not “priced for perfection.”

12. Fact vs. Interpretation Table

13. Open Questions

1. How much of 2026E EBITDA is a transient Hormuz premium versus durable? This determines whether “mid-cycle” is ~$5.5B or ~$6.5B and is the crux of the base-vs-bear split.
2. Phosphate + Trinidad divestiture proceeds, timing, and use of proceeds (buyback vs debt paydown vs reinvestment).
3. Belarus/Russia potash normalization pace — the key bear lever on potash price, and the biggest unknown in the oligopoly’s discipline.
4. Will the new 5% NCIB be spent counter-cyclically? The single clearest future test of whether capital allocation has genuinely improved.
5. Exact management incentive metrics (SEDAR management information circular, not in the EDGAR corpus) — are they FCF/ROIC-linked, and do they discourage a repeat of pro-cyclical growth?
6. Retail return trajectory ex-goodwill — can proprietary mix and Brazil pruning lift Retail ROIC, or is it structurally a low-return distributor?

14. What Must Be True

For the bull case (accumulate and hold for a re-rate):

• Potash tightness is structural: normalized price holds ~$350/t through Jansen’s ramp, with disciplined oligopoly curtailment; farmer application rates fully recover; Belarus logistics stay constrained.
• Nutrien grows potash volume profitably as the low-cost swing producer; Retail lifts proprietary mix and returns; mid-cycle EBITDA proves ~$7B+.
• Capital allocation is counter-cyclical this cycle (5% NCIB spent on weakness); balance sheet de-levers below 1.5x.
• Falsification test: potash contract prices (China/India) roll over as Jansen ramps and Belarus exports climb toward pre-2022 levels — proving the tightness was cyclical, not structural. If MOP breaks below ~$300/t on rising supply within 12–18 months, the bull case is broken.

For the bear case (avoid / expect years of cost-of-capital returns):

• Jansen + recovered Belarus/Russia re-fragment the seaborne market; potash reverts toward $250–300/t; the Hormuz nitrogen premium collapses; a farm-income downturn double-hits fertilizer prices and Retail volumes; Brazil re-impairs.
• Mid-cycle EBITDA proves ~$5.0–5.5B; ROIC stays below cost of capital; management repeats pro-cyclical buybacks.
• Falsification test: potash holds $350+/t through 2027 with oligopoly discipline intact and Nutrien grows volume at bottom-of-curve margins, while Retail ROIC visibly improves on proprietary mix. If mid-cycle EBITDA prints ~$6.5B+ with rising returns, the bear case is broken.

The evidence today sits between the two, which is precisely why the stock trades at a mid-cycle, mid-own-history multiple. The decisive variable is potash-price durability against the Jansen/Belarus supply overhang.

15. Source Appendix

See the source appendix below for the full, dated citation list. Primary sources include: Nutrien’s FY2025 earnings release and MD&A (Form 6-K, filed 2026-02-19); the Q1 2026 release and MD&A (Form 6-K, filed 2026-05-07); the FY2025 40-F annual report (filed 2026-02-27); aggregated financial statement data reconciled to those filings; public price history and news; Moody’s and S&P rating actions; the World Bank commodity outlook; and BHP Jansen disclosures. All non-obvious facts are dated and attributed; management commentary is treated as a hypothesis and validated against filings and external data.

APPENDIX A — Standard Diligence Questionnaire

Supplemental to the research memo. Report date: 2026-07-03. Fact / Interpretation / Assumption labels applied where material.

General

What thoughtful questions have other investors asked about this company? The recurring institutional debates: (1) Is potash tightness structural or a transient post-Ukraine/post-Hormuz artifact — i.e., what is the normalized potash price against the BHP Jansen and Belarus/Russia supply recovery? (2) Is Retail (Nutrien Ag Solutions) a genuine moat and diversifier, or a low-return, goodwill-heavy distribution business that has mostly produced impairments (Brazil/S.America)? (3) Has capital allocation actually improved under Seitz, or is the discipline just a forced correction of the 2022 peak buyback and 18Mt-expansion mistakes? (4) What is true owner free cash flow after real sustaining capex, given “adjusted EBITDA” excludes recurring impairments? (5) Is the ~3.4% dividend the reason to own it, with the upstream as a cheap call option on potash?

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Fact/Interpretation: Mid-cycle, recovering off the 2024 trough. Adjusted EBITDA $6.05B (2025) sits between the $5.4B trough (2024) and the $12.2B peak (2022); 2026 is modestly above mid-cycle because of the transient Hormuz nitrogen/phosphate premium.

Driven by external environment or internal actions? Interpretation: Overwhelmingly external — potash/nitrogen benchmark prices, crop prices, planted acreage and application rates. Internal actions (cost savings ~$200M, capex discipline, divestitures) matter at the margin and lift returns, but the earnings amplitude is set by commodity prices Nutrien does not control.

How stable are revenues? Fact: Upstream revenue is highly cyclical (revenue swung $20.9B→$37.9B→$26.0B in 2020–24); Retail revenue (~$14B) is far more stable, tied to seasonal farm demand. Consolidated revenue is moderately cyclical with a stable Retail floor.

Outlook for products/services? Fact/Assumption: Fertilizer demand grows with global population/protein consumption at low-single-digit volume; the swing is price. Potash is the best-positioned product (disciplined oligopoly, low-cost); phosphate the weakest. Retail grows low-single-digit organically plus proprietary-mix upgrades.

How big is this market — growing, shrinking, domestic or international? Fact: Global — potash ~74–77Mt of annual shipments, nitrogen far larger. Nutrien sells into North America, South America (Brazil), and Australia (Retail) and exports potash/nitrogen globally via Canpotex. The market grows modestly in volume; profit pools swing with price.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Interpretation: Potash is getting more competitive at the margin — BHP Jansen (2027) is the first major greenfield entrant in decades and Belarus/Russia supply has recovered, eroding oligopoly discipline. Ag retail is consolidating (top-8 ~70% of CropLife 100), modestly favorable for Nutrien as #1.

How profitable is the business (ROIC, ROE)? Fact: Through-cycle ROIC ~7–8% (20.7% peak 2022 → 4.9% trough 2024 → 7.8% 2025); ROE 9.0% (2025). Roughly cost-of-capital returns through the cycle — mid-return, not a franchise.

How profitable is the industry — competitors, barriers? Fact/Interpretation: Potash: high barriers (billions/decade per greenfield; incentive price >$500/t vs ~$350/t spot), disciplined oligopoly (top-5 ~80%), bottom-quartile Saskatchewan cost — the most profitable sub-industry. Nitrogen: low barriers, spread business, gas-cost-driven. Phosphate: over-supplied (OCP/Mosaic), price-taking. Ag retail: low barriers to a single store but real local scale/density advantages; low margin.

Can it be easily understood? Fact: Yes — a fertilizer producer + ag retailer. The complexity is in normalizing commodity prices, not the business model.

Undermined by foreign low-cost labor? Interpretation: No — it is capital/resource-intensive, not labor-intensive. The relevant “low-cost” threat is cheaper feedstock/ore abroad (Russian/Gulf gas for nitrogen; Belarus/Russia potash), not labor.

Do brands matter? Interpretation: Minimally upstream (commodities). In Retail, proprietary private-label brands (~$1.1B gross margin) carry modest brand/formulation value and stickiness — the one place brand matters.

Nature of competition? Fact/Interpretation: Upstream — global price competition on a homogeneous commodity; producers curtail volume to defend price (oligopoly discipline in potash). Retail — local service/relationship/credit/agronomy competition against co-ops and independents.

Customers’ switching costs? Interpretation: Low upstream (buyers take the cheapest delivered tonne). Moderate in Retail — grower relationships, agronomy advice, embedded credit (Nutrien Financial), and proprietary products create some captivity, evidenced by gross-margin stability through the crash.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? Interpretation: The Saskatchewan potash reserve base (multi-decade, bottom-quartile cost) is carried at historical cost and is worth far more than book — the key hidden asset. Offsetting it, ~$12.1B of goodwill + $1.7B intangibles (Agrium/retail roll-up) is arguably over-stated given recurring impairments.

Off-balance-sheet liabilities? Fact: Modest — ~$1.28B of capital leases (included in net debt here), a small pension liability (~$221M), and asset-retirement obligations for mines. Nothing alarming.

How conservative is the accounting? Interpretation: Mixed. 2025 was clean (adjusted < reported; a $301M gain stripped out). But “adjusted EBITDA” recurringly excludes downcycle impairments ($824M/2020, $774M/2023, $530M/2024), so cumulative adjusted figures flatter through-cycle economics.

How CapEx-hungry is the business? Fact: Very — capex ~$2.0–2.6B/yr, D&A ~$2.3–2.4B. 2025 capex ($2.0B) ran below D&A (harvest mode). Sustaining capex ~$1.6B; the rest is discretionary growth/automation. This is a capital-intensive business; owner FCF after full capex is ~$2.0B, ~$2.4–2.5B on sustaining-only.

Capital Allocation & Management

How much FCF, and how is it used? Fact: ~$2.0B owner FCF (2025, OCF $4.0B − capex $2.0B). Used for dividends (~$1.06B), buybacks (~$0.56B), and debt paydown. Philosophy (current regime): “structural free cash flow” + cash returns + deleveraging.

Significant acquisitions recently? Fact: No — the opposite. Nutrien is divesting: sold 50% Profertil (Argentina, +$301M gain, Q4 2025); phosphate and Trinidad nitrogen under sale review; Brazil retail and soybean-seed business being pruned/sold. The 2018–2022 Retail roll-up (esp. Brazil) is being unwound at a loss.

Buying back shares? Fact: Yes, but historically pro-cyclically — $4.35B at the 2022 peak (~$90), only $190M at the 2024 trough (~$47), ~$560M in 2025 (~$56). New 5% NCIB approved Feb-2026. ~15% of shares retired since 2021, but much at peak prices. Interpretation: the central capital-allocation critique.

Issuing shares to insiders? Fact: SBC is small (~$163M/yr, ~0.5% of market cap) — not a dilution concern.

Compensation policy of directors/management? Open Question: As a foreign private issuer, Nutrien files no SEC DEF 14A; the management information circular with exact comp metrics is on SEDAR (Canada), not the EDGAR corpus. Strategy language suggests FCF/cash-return-linked incentives (unverified here).

Motivations of management? Interpretation: The current regime (Seitz, since 2022) is credibly focused on capital discipline and cash returns — a correction of the prior peak-cycle growth push. Whether this is durable stewardship or forced discipline will be tested by NCIB timing this cycle.

Valuation & Market Data

ADR, MLP, or K-1 issuer? Fact: None — Nutrien is a Canadian common share dual-listed on the NYSE and TSX; it is a foreign private issuer (files 40-F/6-K) but its NYSE shares are ordinary shares, not an ADR, and it issues a 1099-equivalent, not a K-1. USD-reporting.

Dividend policy? Fact: Quarterly $0.545 (~$2.18/yr, ~3.4% yield), raised every year since the 2018 formation; ~46% payout of adjusted EPS; safe across the cycle (covered by OCF even at the 2024 trough).

How profitable is the business? Fact: Mid — 2025 net margin 8.4%, ROE 9.0%, ROIC 7.8%; peaks near 20%+ ROIC in up-cycles, troughs near 5%.

Is net income diverging from cash from operations? Fact: Yes, cyclically — 2024 NI $674M vs OCF $3.5B (impairments + D&A + WC), 2025 NI $2.3B vs OCF $4.0B. OCF is consistently above NI because of heavy non-cash D&A/impairments; this is normal for a capital-intensive resource business, not a red flag. Watch the seasonal working-capital swings (2025 −$783M drag).

Risks & Downside

What factors would cause the stock to decline? Fact/Interpretation: Falling potash/nitrogen prices (Jansen + Belarus/Russia supply, Hormuz reopening), a crop-price/farm-income downturn hitting fertilizer prices and Retail volumes, Brazil re-impairment, a repeat of pro-cyclical buybacks, or a gas-cost spike compressing nitrogen.

Risk of a catastrophic loss? Interpretation: Very low — investment-grade (Baa2/BBB), ~1.66x leverage, long-life hard assets, positive trough FCF. The realistic downside is years of mediocre cost-of-capital returns and a drift toward the low-$40s, not enterprise impairment.

Chance of a total loss? Interpretation: Negligible barring extreme, sustained mismanagement — the balance sheet and asset base make permanent capital loss implausible.

Recent News & Events

Has the business environment changed recently? Fact: Yes — the Feb-2026 Iran/Strait-of-Hormuz conflict spiked nitrogen/phosphate (urea >$850/t) and is now unwinding on US–Iran de-escalation (June-2026); the Feb-2026 US 25% Canada tariff (potash exempt under USMCA); Scotiabank upgrade to Sector Outperform (PT $80, 30-Jun-2026); a note flagging Q2 consensus as “too high.”

Significant acquisitions? Fact: No — divestitures (Profertil sold; phosphate/Trinidad/Brazil under review). See Capital Allocation.

Change in accounting policies? Fact: None material identified; IFRS filer, consistent presentation.

Recent changes — new markets, facilities, management? Fact: Portfolio simplification, not expansion — Trinidad nitrogen shut and for sale, New Madrid nitrogen offline, Brazil retail rationalized (blenders/locations idled), phosphate strategic review. Ken Seitz permanent CEO since 2022; a CFO transition completed through 2024. The strategic direction is fewer, higher-return assets and more cash returns.

APPENDIX B — Source Appendix

Report date: 2026-07-03. Primary sources prioritized; management commentary treated as hypothesis and validated against filings/external data. All accessed 2026-07-03 unless noted.

Primary — Company Filings & Disclosures (SEC EDGAR, CIK 0001725964; FPI files 40-F/6-K)

1. Nutrien FY2025 earnings release & MD&A — Form 6-K, filed 2026-02-19 (dated 2026-02-18), accession 000119312526057536 (ex99.1, d50313dex991.htm). Consolidated & segment results, 2026 guidance, buyback/dividend notes, adjusted-EBITDA reconciliation. Also nutrien.com/news #1741.
2. Nutrien Q1 2026 results & MD&A — Form 6-K, filed 2026-05-07, accession 000119312526209487. Q1 adj EBITDA $1.11B (Retail $108M, Potash $578M, Nitrogen $482M); potash cash cost <$60/t; $409M returned to holders; FY2026 guidance reaffirmed; portfolio simplification (Trinidad, Brazil, phosphate). Also nutrien.com/news #1746.
3. Nutrien FY2025 Annual Report / 40-F — filed 2026-02-27, accession 000119312526081326. Annual disclosure of record for the FPI.
4. Debt shelf takedown — F-10 / SUPPL / FWP (May-2026, accessions 000119312526238096 / 000119312526239636 / 000119312526242137). Financing activity marker.
5. Schedule 13G (BlackRock) — EDGAR accession 000201238326001655, filed 2026-04-27 (and prior 13G/A filings 2024–2026). Passive index ownership; no SC 13D / activist.
6. Form 11-K (employee benefit plans) — filed 2026-06-26 (×3). Not thesis-relevant.
7. NCIB / buyback authorization — new normal-course issuer bid for up to 5% of shares approved by the Board 2026-02-18 (disclosed in FY2025 release).
8. Note: Nutrien insider transactions file on Canada’s SEDI (not SEC Form 3/4/5) and the management information circular files on SEDAR — neither is in the EDGAR corpus, so no US insider-trade or comp-metric read is available here (an open question).

Primary — Quantitative Financial Data (reconciled to filings; the filing governs)

9. Aggregated financial statement data — income statement, balance sheet, cash flow, profitability ratios, enterprise value and valuation multiples (annual FY2020–FY2025), plus the Q1 2026 earnings-call transcript (call dated 2026-05-07). Third-party aggregated data reconciled to the FY2025 release and Q1 2026 6-K (the filing governs).

Primary — Market & Factor Data

10. Public price history — adjusted & unadjusted daily OHLCV, 2018-01-02 → 2026-07-02. Five-year event map; ATH adj close $98.48 (2022-04-18); 52-wk range $52.32–$82.59; last $65.06.
11. Own-history valuation percentiles — ranks (composite 50.5th; P/E 34.4th @13.24x; P/B 66.4th @1.24x; P/S 50.7th @1.13x; BVPS $52.40; TTM EPS $4.91).
12. Financial news — items incl. Scotiabank upgrade to Sector Outperform, PT $80 (2026-06-30); “Q2 consensus may be too high” (2026-06-25); Iran/Hormuz peace-progress fertilizer moves (2026-06-12/16); Ocehan mini-tender notice (2026-06-12).
13. a quantitative factor model — /stock-loadings, /leaderboard, /stock-info, /related-stocks for NTR: OilPrice β ~0.65, Value β ~0.47, Materials/Canada tilts; market beta 0.41; y1 +12.2%, m3 −42.8% ann, y5 +4.9% ann / −58% max DD; rs_peak −33.9%. Factor peers MEOH/CF/LXU/CNQ.

Secondary — Industry, Macro & Ratings (dated, attributed)

14. World Bank Commodity Markets Outlook / Blogs (2026) — fertilizer price index +30%+ 2026 (urea ~+60%, MOP ~+12% then −6% 2027); Hormuz supply-shock analysis.
15. CNBC (2026-03-25); StoneX; FAO — urea >$850/t (Apr-2026), >30% of urea trade / ~25% ammonia & phosphate disrupted by Hormuz closure; Qatar/Iran export suspensions.
16. BNN Bloomberg (2026-02-06) — potash below incentive price; K+S mid-curve breakeven ~$350/t; new-supply incentive >$500/t.
17. BHP; NS Energy; Northern Miner — Jansen greenfield first production ~mid-2027, ~8.5Mtpa Stage 1, path to 16–17Mtpa.
18. REFORM.news; PBS; RFE/RL; Argus — Belarus ~11.6Mt potash exports (2025) via Russian ports; US lifted Belarus potash sanctions (2025); Russia ~12–13Mt.
19. CropLife 100 — Nutrien Ag Solutions #1 US ag retailer; top-8 ~70% of sales (consolidation).
20. Moody’s (affirmation 2025-05-29, Baa2 stable, cbonds.com/news/3425353); S&P BBB stable.
21. Argus; Globe & Mail; RealAgriculture — Feb-2026 US 25% Canada tariff (10% energy); USMCA-compliant fertilizer exempt; US price-fixing probe into Canadian fertilizer; Seitz/18Mt-expansion pause commentary.
22. BusinessWire / Nutrien (2026-06-12) — Ocehan LLC unsolicited “mini-tender” for up to 100,000 shares at C$70.20 (~25% below market); Nutrien cautioned holders.

Analytical Frameworks

27. Greenwald & Kahn, “Competition Demystified” — moat typing (supply/cost + scale-with-captivity), share-stability & ROIC tests.
28. Marathon (Chancellor), “Capital Returns” — supply-side capital-cycle analysis (potash: 2024 trough → 2025 recovery → 2027 Jansen supply overhang).